{"id":39985,"date":"2017-07-27T06:20:23","date_gmt":"2017-07-27T10:20:23","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=39985"},"modified":"2017-07-27T04:02:38","modified_gmt":"2017-07-27T08:02:38","slug":"moleculin-biotech-inc-nasdaqmbrx-could-benefit-more-than-anticipated-from-the-agreement-with-md-anderson-on-leukemia-drug-annamycin","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/moleculin-biotech-inc-nasdaqmbrx-could-benefit-more-than-anticipated-from-the-agreement-with-md-anderson-on-leukemia-drug-annamycin-39985","title":{"rendered":"Moleculin Biotech Inc. (NASDAQ:MBRX) Could Benefit More Than Anticipated From The Agreement with MD Anderson on Leukemia Drug, Annamycin"},"content":{"rendered":"<p class=\"MsoNormal\"><span style=\"font-family: 'Times New Roman','serif';\">Latest sources have revealed the fact that Moleculin Biotech Inc. (NASDAQ:MBRX) has finally signed an agreement with MD Anderson Cancer Center. The follows their deal which involved the Leukemia Drug called Annamycin. The signing of this agreement had some underlying deals which includes licensing agreement. Apparently, Moleculin is signing a new technology agreement with MD Anderson Cancer Centre. The agreement will be based on the new patient application; an application which its intend is to file any data relating to Annamycin drug use, order and distribution as far as the treatment of relapse or refractory acute myeloid leukemia (AML) is concerned. <\/span><\/p>\n<p class=\"MsoNormal\"><b><span style=\"font-family: 'Times New Roman','serif';\">Key Patent Issues Expected to Resolve with New Agreement <\/span><\/b><\/p>\n<p class=\"MsoNormal\"><span style=\"font-family: 'Times New Roman','serif';\">According to different sources; based on an interview with Moleculin CEO, Walter Klemp, it is now crystal clear that the new agreement is based on the statement from the CEO, which said, \u201cIn anticipation of beginning our planned clinical trials for Annamycin, one of our priorities has been to use the best possible protection for our intellectual property\u201d In addition, the CEO <\/span><a href=\"https:\/\/finance.yahoo.com\/news\/moleculin-signs-agreement-md-anderson-113000430.html\" target=\"_blank\" rel=\"noopener\"><span style=\"font-family: 'Times New Roman','serif';\">said<\/span><\/a><span style=\"font-family: 'Times New Roman','serif';\">, \u201c Some key patent applications had yet to be filed and signing a new license agreement with MD Anderson clears the way for those patents\u201d<\/span><\/p>\n<p class=\"MsoNormal\"><b><span style=\"font-family: 'Times New Roman','serif';\">Benefits to be Accrued from Collaborating with MD Anderson <\/span><\/b><\/p>\n<p class=\"MsoNormal\"><span style=\"font-family: 'Times New Roman','serif';\">From the look of things and from the different perspectives expressed by different sources, it is a fact that with MD Anderson on board, Moleculin Company will be in a position to gain ground because of the fact that the issues associated with patent rights have been resolved by MD Anderson. With MD Anderson on board, Moleculin will also be able to manufacture its new drug and distribute it through the MD Anderson distribution chains without the need to worry about patent issues and licensing in the long run. Considering that Moleculin has done a series of clinical trials on the new drug, MD Anderson being a Center for Cancer Treatment will make the use of drug as more efficient. <\/span><\/p>\n<p class=\"MsoNormal\"><span style=\"font-family: 'Times New Roman','serif';\">With the signing of the agreement with MD Anderson Cancer Center, Moleculin is now is a good position to benefit from the collaboration. This has been <\/span><a href=\"https:\/\/finance.yahoo.com\/news\/moleculin-signs-agreement-md-anderson-113000430.html\"><span style=\"font-family: 'Times New Roman','serif';\">echoed<\/span><\/a><span style=\"font-family: 'Times New Roman','serif';\"> by Moleculin CEO, Klemp who said, \u201cWe have benefited greatly from our collaboration with MD Anderson and this license helps ensure that collaboration continues\u201d<\/span><br \/>\n&nbsp;<\/p>\n<p class=\"MsoNormal\"><span style=\"font-family: 'Times New Roman','serif';\">Moleculin Biotech stocks closed yesterday\u2019s session at $2.18 which was an improvement of $0.17 or 8.46%.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Latest sources have revealed the fact that Moleculin Biotech Inc. (NASDAQ:MBRX) has finally signed an agreement with MD Anderson Cancer Center. The follows their deal [&hellip;]<\/p>\n","protected":false},"author":15,"featured_media":39990,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[12797,12796,12798],"stock_ticker":[],"class_list":["post-39985","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-moleculin-biotech-inc","tag-moleculin-biotech-inc-nasdaqmbrx","tag-nasdaqmbrx","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Moleculin Biotech Inc. (NASDAQ:MBRX) Could Benefit More Than Anticipated From The Agreement with MD Anderson on Leukemia Drug, Annamycin - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/moleculin-biotech-inc-nasdaqmbrx-could-benefit-more-than-anticipated-from-the-agreement-with-md-anderson-on-leukemia-drug-annamycin-39985\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Moleculin Biotech Inc. (NASDAQ:MBRX) Could Benefit More Than Anticipated From The Agreement with MD Anderson on Leukemia Drug, Annamycin - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Latest sources have revealed the fact that Moleculin Biotech Inc. (NASDAQ:MBRX) has finally signed an agreement with MD Anderson Cancer Center. The follows their deal [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/moleculin-biotech-inc-nasdaqmbrx-could-benefit-more-than-anticipated-from-the-agreement-with-md-anderson-on-leukemia-drug-annamycin-39985\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-07-27T10:20:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/07\/39989-images__5_.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"168\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Benjamin Roussey\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Benjamin Roussey\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/moleculin-biotech-inc-nasdaqmbrx-could-benefit-more-than-anticipated-from-the-agreement-with-md-anderson-on-leukemia-drug-annamycin-39985#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/moleculin-biotech-inc-nasdaqmbrx-could-benefit-more-than-anticipated-from-the-agreement-with-md-anderson-on-leukemia-drug-annamycin-39985\"},\"author\":{\"name\":\"Benjamin Roussey\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\"},\"headline\":\"Moleculin Biotech Inc. (NASDAQ:MBRX) Could Benefit More Than Anticipated From The Agreement with MD Anderson on Leukemia Drug, Annamycin\",\"datePublished\":\"2017-07-27T10:20:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/moleculin-biotech-inc-nasdaqmbrx-could-benefit-more-than-anticipated-from-the-agreement-with-md-anderson-on-leukemia-drug-annamycin-39985\"},\"wordCount\":413,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/moleculin-biotech-inc-nasdaqmbrx-could-benefit-more-than-anticipated-from-the-agreement-with-md-anderson-on-leukemia-drug-annamycin-39985#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/07\/39989-images__5_.jpeg\",\"keywords\":[\"Moleculin Biotech Inc.\",\"Moleculin Biotech Inc. (NASDAQ:MBRX)\",\"NASDAQ:MBRX\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/moleculin-biotech-inc-nasdaqmbrx-could-benefit-more-than-anticipated-from-the-agreement-with-md-anderson-on-leukemia-drug-annamycin-39985#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/moleculin-biotech-inc-nasdaqmbrx-could-benefit-more-than-anticipated-from-the-agreement-with-md-anderson-on-leukemia-drug-annamycin-39985\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/moleculin-biotech-inc-nasdaqmbrx-could-benefit-more-than-anticipated-from-the-agreement-with-md-anderson-on-leukemia-drug-annamycin-39985\",\"name\":\"Moleculin Biotech Inc. (NASDAQ:MBRX) Could Benefit More Than Anticipated From The Agreement with MD Anderson on Leukemia Drug, Annamycin - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/moleculin-biotech-inc-nasdaqmbrx-could-benefit-more-than-anticipated-from-the-agreement-with-md-anderson-on-leukemia-drug-annamycin-39985#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/moleculin-biotech-inc-nasdaqmbrx-could-benefit-more-than-anticipated-from-the-agreement-with-md-anderson-on-leukemia-drug-annamycin-39985#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/07\/39989-images__5_.jpeg\",\"datePublished\":\"2017-07-27T10:20:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/moleculin-biotech-inc-nasdaqmbrx-could-benefit-more-than-anticipated-from-the-agreement-with-md-anderson-on-leukemia-drug-annamycin-39985#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/moleculin-biotech-inc-nasdaqmbrx-could-benefit-more-than-anticipated-from-the-agreement-with-md-anderson-on-leukemia-drug-annamycin-39985\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/moleculin-biotech-inc-nasdaqmbrx-could-benefit-more-than-anticipated-from-the-agreement-with-md-anderson-on-leukemia-drug-annamycin-39985#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/07\/39989-images__5_.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/07\/39989-images__5_.jpeg\",\"width\":300,\"height\":168},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/moleculin-biotech-inc-nasdaqmbrx-could-benefit-more-than-anticipated-from-the-agreement-with-md-anderson-on-leukemia-drug-annamycin-39985#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Moleculin Biotech Inc. (NASDAQ:MBRX) Could Benefit More Than Anticipated From The Agreement with MD Anderson on Leukemia Drug, Annamycin\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\",\"name\":\"Benjamin Roussey\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"caption\":\"Benjamin Roussey\"},\"description\":\"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Moleculin Biotech Inc. (NASDAQ:MBRX) Could Benefit More Than Anticipated From The Agreement with MD Anderson on Leukemia Drug, Annamycin - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/moleculin-biotech-inc-nasdaqmbrx-could-benefit-more-than-anticipated-from-the-agreement-with-md-anderson-on-leukemia-drug-annamycin-39985","og_locale":"en_US","og_type":"article","og_title":"Moleculin Biotech Inc. (NASDAQ:MBRX) Could Benefit More Than Anticipated From The Agreement with MD Anderson on Leukemia Drug, Annamycin - Wall Street PR","og_description":"Latest sources have revealed the fact that Moleculin Biotech Inc. (NASDAQ:MBRX) has finally signed an agreement with MD Anderson Cancer Center. The follows their deal [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/moleculin-biotech-inc-nasdaqmbrx-could-benefit-more-than-anticipated-from-the-agreement-with-md-anderson-on-leukemia-drug-annamycin-39985","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2017-07-27T10:20:23+00:00","og_image":[{"width":300,"height":168,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/07\/39989-images__5_.jpeg","type":"image\/jpeg"}],"author":"Benjamin Roussey","twitter_misc":{"Written by":"Benjamin Roussey","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/moleculin-biotech-inc-nasdaqmbrx-could-benefit-more-than-anticipated-from-the-agreement-with-md-anderson-on-leukemia-drug-annamycin-39985#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/moleculin-biotech-inc-nasdaqmbrx-could-benefit-more-than-anticipated-from-the-agreement-with-md-anderson-on-leukemia-drug-annamycin-39985"},"author":{"name":"Benjamin Roussey","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d"},"headline":"Moleculin Biotech Inc. (NASDAQ:MBRX) Could Benefit More Than Anticipated From The Agreement with MD Anderson on Leukemia Drug, Annamycin","datePublished":"2017-07-27T10:20:23+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/moleculin-biotech-inc-nasdaqmbrx-could-benefit-more-than-anticipated-from-the-agreement-with-md-anderson-on-leukemia-drug-annamycin-39985"},"wordCount":413,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/moleculin-biotech-inc-nasdaqmbrx-could-benefit-more-than-anticipated-from-the-agreement-with-md-anderson-on-leukemia-drug-annamycin-39985#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/07\/39989-images__5_.jpeg","keywords":["Moleculin Biotech Inc.","Moleculin Biotech Inc. (NASDAQ:MBRX)","NASDAQ:MBRX"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/moleculin-biotech-inc-nasdaqmbrx-could-benefit-more-than-anticipated-from-the-agreement-with-md-anderson-on-leukemia-drug-annamycin-39985#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/moleculin-biotech-inc-nasdaqmbrx-could-benefit-more-than-anticipated-from-the-agreement-with-md-anderson-on-leukemia-drug-annamycin-39985","url":"https:\/\/cablemanpro.com\/wallstreetpr\/moleculin-biotech-inc-nasdaqmbrx-could-benefit-more-than-anticipated-from-the-agreement-with-md-anderson-on-leukemia-drug-annamycin-39985","name":"Moleculin Biotech Inc. (NASDAQ:MBRX) Could Benefit More Than Anticipated From The Agreement with MD Anderson on Leukemia Drug, Annamycin - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/moleculin-biotech-inc-nasdaqmbrx-could-benefit-more-than-anticipated-from-the-agreement-with-md-anderson-on-leukemia-drug-annamycin-39985#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/moleculin-biotech-inc-nasdaqmbrx-could-benefit-more-than-anticipated-from-the-agreement-with-md-anderson-on-leukemia-drug-annamycin-39985#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/07\/39989-images__5_.jpeg","datePublished":"2017-07-27T10:20:23+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/moleculin-biotech-inc-nasdaqmbrx-could-benefit-more-than-anticipated-from-the-agreement-with-md-anderson-on-leukemia-drug-annamycin-39985#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/moleculin-biotech-inc-nasdaqmbrx-could-benefit-more-than-anticipated-from-the-agreement-with-md-anderson-on-leukemia-drug-annamycin-39985"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/moleculin-biotech-inc-nasdaqmbrx-could-benefit-more-than-anticipated-from-the-agreement-with-md-anderson-on-leukemia-drug-annamycin-39985#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/07\/39989-images__5_.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/07\/39989-images__5_.jpeg","width":300,"height":168},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/moleculin-biotech-inc-nasdaqmbrx-could-benefit-more-than-anticipated-from-the-agreement-with-md-anderson-on-leukemia-drug-annamycin-39985#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Moleculin Biotech Inc. (NASDAQ:MBRX) Could Benefit More Than Anticipated From The Agreement with MD Anderson on Leukemia Drug, Annamycin"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d","name":"Benjamin Roussey","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","caption":"Benjamin Roussey"},"description":"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/39985","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=39985"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/39985\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/39990"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=39985"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=39985"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=39985"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=39985"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}